Abstract
The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Current Pharmaceutical Design
Title:The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Volume: 27 Issue: 23
Author(s): Nikolaos Sofikitis*, Aris Kaltsas, Fotios Dimitriadis, Jens Rassweiler, Nikolaos Grivas, Athanasios Zachariou, Apostolos Kaponis, Panagiota Tsounapi, Napoleon Paterakis, Andreas Karagiannis, Sotirios Skouros, Ioannis Giannakis, Ioannis Champilomatis, Minas Paschopoulos, Diamantis Daphnis, Ioannis Giakoumakis, Melinda R.Gabales, Jo Ben M. Chua, Pedro L. Lantin III, Charalampos Mamoulakis and Atsushi Takenaka
Affiliation:
- Department of Urology, Ioannina University School of Medicine, Ioannina,Greece
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Abstract: The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Export Options
About this article
Cite this article as:
Sofikitis Nikolaos *, Kaltsas Aris , Dimitriadis Fotios , Rassweiler Jens , Grivas Nikolaos , Zachariou Athanasios , Kaponis Apostolos , Tsounapi Panagiota , Paterakis Napoleon , Karagiannis Andreas , Skouros Sotirios , Giannakis Ioannis , Champilomatis Ioannis , Paschopoulos Minas , Daphnis Diamantis , Giakoumakis Ioannis , R.Gabales Melinda , M. Chua Ben Jo , Lantin III L. Pedro, Mamoulakis Charalampos and Takenaka Atsushi , The Effect of PDE5 Inhibitors on the Male Reproductive Tract, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612826666200226121510
DOI https://dx.doi.org/10.2174/1381612826666200226121510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Co-Editor
Current Vascular Pharmacology Nitric Oxide and its Role During Pregnancy: From Ovulation to Delivery
Current Pharmaceutical Design Clinical Uses of 1-alpha-hydroxycholecalciferol
Current Vascular Pharmacology Reduction in the Ratio of Low-density Lipoprotein Cholesterol to Highdensity Lipoprotein Cholesterol is Associated with Increased Risks of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research Correspondence Section
Current Drug Targets Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function
Current Pharmaceutical Design Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala
Current Drug Safety Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Increased Susceptibility to Oxidative Death of Lymphocytes from Alzheimer Patients Correlates with Dementia Severity
Current Alzheimer Research Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Lessons from the REACH Registry in Europe
Current Vascular Pharmacology Anti-Angiogenic Activity of Curcumin in Cancer Therapy: A Narrative Review
Current Vascular Pharmacology Cabozantinib in Thyroid Cancer
Recent Patents on Anti-Cancer Drug Discovery High Fat Diet-Induced Obesity Stimulate Depressive Behavior in Rats
Current Psychopharmacology